<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
Certification and Notice of Termination of Registration under
Section 12(g) of the Securities Exchange Act of 1934 or Suspension
of Duty to File Reports Under Sections 13 and 15(d) of the
Securities Exchange Act of 1934.
Commission File No. 0-13275
SPI PHARMACEUTICALS, INC.
(Exact name of registrant as specified in charter)
3300 Hyland Ave.
Costa Mesa, CA 92626
(Address, including zip code, and telephone number, including
area code, of registrant's principal offices)
Common Stock
par value $.01 per share
(Titles of each class of securities covered by this Form)
NONE
Title of all other classes of securities for which a duty to file
reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule
provision(s) relied upon to terminate or suspend the duty to file
reports.
Rule 12g-4(a)(1)(i) [ ] Rule 12h-3(b)(1)(ii) [ ]
Rule 12g-4(a)(1)(ii) [ ] Rule 12h-3(b)(2)(i) [ ]
Rule 12g-4(a)(2)(i) [ ] Rule 12h-3(b)(2)(ii) [ ]
Rule 12g-4(a)(2)(ii) [X] Rule 15d-6 [ ]
Rule 12h-3(b)(1)(i) [X]
Approximate number of holders of record as of the certification
date or notice date:
None
Pursuant to the requirements of the Securities Exchange Act of
1934, SPI Pharmaceuticals, Inc., the successor to the Registrant,
has caused this certification/notice to be signed on its behalf by
the undersigned duly authorized persons.
/s/ M'Liss Jones Kane
DATE: November 10, 1994 By: ____________________________
Name: M'Liss Jones Kane
Title: General Counsel
<PAGE>
